A next-generation testosterone candidate, minus an unwanted metabolite.
Lennham has shown that d3-testosterone is highly resistant to metabolism to estradiol, the primary estrogen metabolized from testosterone.
Lennham holds a broad patent covering d3-testosterone to treat male hypogonadism. Additional applications are pending.